NEW YORK (GenomeWeb) – ERS Genomics said today that it has licensed its CRISPR-Cas9 genome editing patents to the NMI Natural and Medical Sciences Institute at the University of Tübingen and its affiliate NMI TT Pharmaservices.

Under the terms of the non-exclusive licensing deal, NMI and NMI TT will gain access to the ERS patents in order to use them to expand their own custom cell-based research service offerings. Financial details of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.